Biomea Fusion (BMEA) Stock Jumps on Durable Diabetes Drug Data: Outlook, Analyst Targets and Key Risks as of December 5, 2025
Biomea Fusion shares rose over 10% Friday after the company reported 52-week Phase II data showing its experimental diabetes drug icovamenib sustained HbA1c reductions months after treatment ended. The results, presented at WCIRDC in Los Angeles, included no serious treatment-related adverse events. Despite the gain, Biomea’s stock remains down about 80% over the past year.
